Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitlePegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial.AuthorsSchiffmann, Raphael; Goker‐Alpan, Ozlem; Holida, Myrl; Giraldo, Pilar; Barisoni, Laura; Colvin, Robert B.; Jennette, Charles J.; Maegawa, Gustavo; Boyadjiev, Simeon A.; Gonzalez, Derlis; Nicholls, Kathy; Tuffaha, Ahmad; Atta, Mohamed G.; Rup, Bonita; Charney, Martha R.; Paz, Alona; Szlaifer, Mali; Alon, Sari; Brill‐Almon, Einat; Chertkoff, RaulPublicationJournal of Inherited Metabolic Disease, 2019, Vol 42, Issue 3, p534ISSN0141-8955Publication typeArticleDOI10.1002/jimd.12080